Released on: April 16, 2008, 8:50 am

Press Release Author: GTCbio

Industry: Biotech

Press Release Summary: Dr. Matthew Olson, Principle Research Scientist at Johnson &
Johnson will give a presentation at GTCbio's 3rd Assay Development & Screening
Technologies Conference on June 5-6, 2008 in San Francisco, CA. Dr. Olsen will
present on "Coupling Label-free and Flouormetric Functional Assays with Biophysical
Binding Assays: A Comparison of Positives from an HTS Campaign."

Press Release Body: HTS campaigns continue to push assay limits. As a consequence,
the use of labeled substrates and secondary detection methods that minimize
interference issues are often employed. However, fluorescent labeling of a
particular substrate can often result in the generation of a substrate that no
longer resembles the physiological target. In addition, secondary detection
techniques often result in an assay where initial velocity requirements are lost. To
employ label-free systems, experimenters have had to face the reality of using of
substrates that amplify interference issues and use substrate concentrations well
above the KM-value (negating initial velocity conditions). The coupling of
high-throughput mass spectroscopy (HTMS) in a functional assay eliminates the issues
of using fluorgenic substrates and may allow the functional assay to more closely
reflect the in vivo condition. The sensitivity of HTMS assays (when utilizing single
ion monitoring) rivals optically based functional assays eliminating optical
interference. HTMS assays eliminate complications from coupling enzymes, secondary
detection methods, and allows for the examination of bifuctional enzyme reactions
independently. In the present study, functional assays are coupled with a label-free
biophysical binding assay (ThermofluorTM) giving an additional means of evaluating
compound activity. The overlap between these orthogonal in vitro technologies
enables rapid lead generation, optimization and development.
GTCbio\'s 3rd Assay Development and Screening Technologies conference provides
attendees with critical information to utilize in the discovery and development of
assays, while keeping them informed about the latest screening technologies for both
high-throughput screening and high-content screening. Topics being covered include
cell based assays, high throughput screening, high content screening, in vitro
assays and screening, novel assay and screening technologies, and target validation.
For more information visit www.gtcbio.com.
ABOUT GTCbio
GTCbio organizes conferences specifically for the biomedical and biopharmaceutical
industries. Our goal is to facilitate the exchange of biopharmaceutical and
biomedical intelligence between industry leaders, academic and government
organizations, and the financial community.
GTCbio is a subsidiary of Global Technology Community, LLC, a privately held company
founded in 2002.
Contact: GTCBIO (626) 256-6405, (626) 256-6460 fax, nina.tran@gtcbio.com


Web Site: http://www.gtcbio.com

Contact Details: Contact: GTCBIO (626) 256-6405, (626) 256-6460 fax,
nina.tran@gtcbio.com